NSCLC FAQs Interactive On-Demand Webcast
Release Date: Monday, June 2, 2014
Expiration Date: Monday, June 1, 2015
This CME/CE-certified activity, developed by Karen L. Reckamp, MD, MS, is based on frequently asked questions posed during lectures presented by the faculty at the live grand rounds Histological and Pathological Underpinnings of Non-Small Cell Lung Cancers in 2013 and 2014 at academic centers and medical institutions throughout the United States.
To access this activity, please click the ‘launch’ button above. You will then be redirected to the Medscape Website to participate.
Non-small cell lung cancers are characteristically asymptomatic early on and therefore are typically diagnosed in the advanced stage. Traditional treatment regimens such as platinum doublets typically yield a host of side effects that prove extremely taxing on frail patients. Fortunately, novel agents and regimens are emerging that are offering promising results in clinical trials and that may greatly improve outcomes in patients with lung cancer, particularly those with NSCLC. The multidisciplinary care team must be able to appropriately incorporate these data into the evolving NSCLC therapeutic landscape and select a treatment regimen that is personalized for their patients based on individual biopsy results. This frequently asked questions activity, based on the series of live grand rounds and webinars, seeks to address these educational needs while bridging existing knowledge and performance gaps to improve the clinical outcomes of patients with NSCLC.
This activity was developed for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, oncology nurses, and other members of the multidisciplinary healthcare team responsible for the diagnosis and management of patients with non-small cell lung cancers (NSCLCs).
Upon completion of this activity, participants should be able to:
- Identify specific pathological implications and histological subtypes of NSCLC that drive treatment decisions
- Discuss the latest pathological evidence that facilitates individualized treatment planning
- Incorporate evidence-based novel immunotherapeutic treatment strategies when managing patients with NSCLC
- Explain the latest clinical trial data on established and investigational therapeutic options for patients with NSCLC
- Provide appropriate care and counsel for patients and their families
Karen L. Reckamp, MD, MS
Associate Professor, Department of Medical Oncology
City of Hope and Beckman Research Institute
Disclosure: Advisory Board: Amgen, Inc., Boehringer-Ingelheim
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™ or ANCC contact hours, you must receive a minimum score of 75% on the post-test.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 0.50 contact hours is provided by Postgraduate Institute for Medicine.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity. For technical assistance, contact CME@medscape.net
To access activities, users will need:
Internet Explorer 8.x or higher, the latest versions of Firefox or Safari, or any other W3C standards compliant browser.
Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback.
Occasionally other additional software may be required such as PowerPoint or Adobe Acrobat Reader.
There is no fee for this educational activity.
Jointly sponsored/co-provided by:
This activity is supported by an educational grant from Bristol-Myers Squibb Company and Lilly.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.